Genetic testing for ultra-early detection of cancer

Quantify future “cancer risk” from blood genes using state-of-the-art genetic analysis technology.

In general, cancer testing equipment includes imaging such as PET, CT, and MRI, as well as endoscopy, but cancer cannot be detected until it reaches a certain size. In addition, the size that is already visible is said to be the result of the growth of one cancer cell over a long period of time, 5 to 20 years.

We offer “cancer gene testing” to support “cancer-free body building” by learning the risk of cancer existence in advance, rather than treating the disease after it has developed.

Inspection Contents

1. To examine acquired changes in cancer-related genes in the blood.

This test examines the risk of the presence of very small cancer cells before they develop into cancer, which increases due to acquired factors such as lifestyle, living environment, stress, and aging, rather than genetic risk (constitution) inherited from parents. Knowing the future risk of cancer can be useful for prevention.

2. evaluation of “cancer cell presence risk” quantified from 1 to 100 using state-of-the-art analysis technology

Genetic materials such as DNA and RNA are extracted from blood and tested for their concentration and cancer-related genes released into the blood that are associated with about 70 different types of cancer. The risk of the presence of very small cancer cells before they grow into cancer is quantified and evaluated on a scale of 1 to 100.

FreeDNA concentration

Measures the concentration of DNA in the blood. High concentrations may reflect cancer or some other abnormality.

Gene Expression Analysis

The degree of activity of genes (axons) that cause cancer growth is examined. The 47 genes (RNA) involved in various cancers are analyzed and reflected in the cancer risk assessment.

Mutation and methylation analysis

Examines the breakdown of cancer-suppressor genes (brakes). Abnormalities can cause normal cells to become cancerous, or fail to suppress cancer cells.

Cancer Risk Assessment

The results of FreeDNA concentration and gene expression analysis, as well as other patient data, are used to quantify cancer risk using proprietary algorithms.

Inspection Flow

It takes about 3 weeks from the date of blood collection to the diagnosis by the test result report.


The director will explain the details of the examination and ask you to fill out a medical questionnaire.

drawing blood

Approximately 25 ml of blood will be drawn. Only this amount is needed for the test.


Over a period of approximately three weeks, the blood is tested for cancer-related genes.


The director will explain the results of the diagnosis based on the test result report. The director will provide guidance and advice on treatment methods for “cancer prevention” suited to each patient according to the results.

A detailed report will be given to the patient along with guidance and advice from the Director.

  • Result reports (cancer risk assessment, gene expression analysis, FreeDNA concentration, mutation analysis, methylation analysis, hematology)
  • Inspection report and summary
  • Guidance for Utilization of Result Reports
  • Cancer Prevention through Lifestyle Improvement Resources


(data) itemFee (JPY, excl. VAT)
  • All of the above fees are only applicable to patients who can present a valid Japanese health insurance card and who are fluent in Japanese and have no difficulty with the counseling process. For other patients, please refer to the estimate after the counseling.